Newsbenzinga
Reported Earlier, Halozyme Therapeutics Prices Upsized $1.3B Offering Of 1.50% Convertible Senior Notes Due 2033
· Published
Article summary
Please check the source for details.
An excerpt from the original article.Loading news article.
Comments —
Loading comments…